{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Balaxi Pharmaceuticals Ltd
Balaxi Pharmaceuticals Ltd is Rated Strong Sell
Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 Nov 2025. However, the analysis and financial metrics discussed below reflect the company’s current position as of 15 March 2026, providing investors with the latest insights into the stock’s performance and outlook.
Balaxi Pharmaceuticals Ltd is Rated Strong Sell
Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 Nov 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed below represent the stock's current position as of 03 March 2026, providing investors with the latest insights into its performance and outlook.
Balaxi Pharmaceuticals Ltd is Rated Strong Sell
Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 Nov 2025, reflecting a reassessment of the company’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 20 February 2026, providing investors with the latest perspective on the stock’s performance and prospects.
Balaxi Pharmaceuticals Ltd is Rated Strong Sell
Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 Nov 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here represent the stock's current position as of 09 February 2026, providing investors with an up-to-date view of its performance and outlook.
Balaxi Pharmaceuticals Gains 0.91%: 2 Key Factors Driving the Week
Balaxi Pharmaceuticals Ltd recorded a modest weekly gain of 0.91% to close at Rs.24.38 on 30 January 2026, underperforming the broader Sensex which advanced 1.62% over the same period. The week was marked by a stabilisation in the company’s quarterly financial performance amid ongoing challenges, with the stock reacting to key earnings updates and market sentiment shifts. Despite the slight price appreciation, Balaxi remains under pressure relative to the benchmark index, reflecting persistent sector headwinds and valuation concerns.
Balaxi Pharmaceuticals Ltd is Rated Strong Sell
Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 Nov 2025, reflecting a reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below represent the company’s current position as of 29 January 2026, providing investors with the latest data to inform their decisions.
Balaxi Pharmaceuticals Reports Flat Quarterly Performance Amid Long-Term Challenges
Balaxi Pharmaceuticals Ltd has reported a flat financial performance for the quarter ended December 2025, marking a notable shift from its previous negative trend. Despite the absence of key negative triggers, the company continues to face significant headwinds, reflected in its long-term stock underperformance relative to the broader market.
Are Balaxi Pharmaceuticals Ltd latest results good or bad?
Balaxi Pharmaceuticals Ltd's latest Q3 FY26 results show a slight decline in net sales and a drastic 94.22% drop in net profit, indicating significant operational challenges and profitability issues, despite some sequential recovery. Investors should be cautious and monitor future performance closely.
Balaxi Pharmaceuticals Q3 FY26: Profitability Crisis Deepens Amid Margin Collapse
Balaxi Pharmaceuticals Ltd. reported a devastating 94.22% year-on-year decline in net profit for Q3 FY26, with earnings collapsing to just ₹0.31 crores from ₹5.36 crores in the same quarter last year. The micro-cap pharmaceutical company, with a market capitalisation of ₹137.00 crores, saw its profit margins evaporate to a mere 0.43%, down from 7.31% in Q3 FY25, as an extraordinary tax burden and operational inefficiencies ravaged the bottom line. The stock, trading at ₹25.14, has plunged 62.72% over the past year, underperforming the pharmaceutical sector by a staggering 86.83 percentage points.
Balaxi Pharmaceuticals Ltd is Rated Strong Sell
Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market trends.
Balaxi Pharmaceuticals Ltd is Rated Strong Sell
Balaxi Pharmaceuticals Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 12 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with an up-to-date view of the company’s performance and outlook.
Why is Balaxi Pharma falling/rising?
On 12-Dec, Balaxi Pharmaceuticals Ltd witnessed a sharp decline in its share price, falling by 8.96% to close at ₹30.06. This drop marks a continuation of a prolonged downtrend, with the stock hitting a fresh 52-week low of ₹29.55 during the trading session.
Balaxi Pharma’s Evaluation Metrics Revised Amid Challenging Market Conditions
Balaxi Pharma has experienced a revision in its evaluation metrics, reflecting a more cautious market assessment. This shift is driven by changes across key analytical parameters including quality, valuation, financial trends, and technical outlook, signalling a complex environment for this pharmaceuticals and biotechnology microcap.
Is Balaxi Pharma overvalued or undervalued?
As of November 17, 2025, Balaxi Pharma is considered very attractive and undervalued with a PE ratio of 13.68, an EV to EBIT of 10.81, and a Price to Book Value of 0.83, making it a compelling investment opportunity despite a year-to-date stock decline of 50.32%.
Why is Balaxi Pharma falling/rising?
As of 17-Nov, Balaxi Pharmaceuticals Ltd's stock price has declined to Rs. 35.92, marking a 4.03% drop and a new 52-week low. The company faces significant financial challenges, including a 53.75% negative return over the past year and reduced institutional interest, contributing to a lack of investor confidence.
Is Balaxi Pharma overvalued or undervalued?
As of November 12, 2025, Balaxi Pharma is considered undervalued with a PE ratio of 14.43, significantly lower than peers like Bajaj Finance and Bajaj Finserv, and has underperformed against the Sensex with a year-to-date return of -47.57%.
Balaxi Pharmaceuticals Experiences Quality Grade Change Amid Mixed Financial Performance
Balaxi Pharmaceuticals has experienced a revision in its evaluation, marked by a 15.04% sales growth over five years, despite a 4.77% decline in EBIT. With a low net debt to equity ratio of 0.11 and a 25.08% return on equity, the company faces competitive challenges in the market.
How has been the historical performance of Balaxi Pharma?
Balaxi Pharma's historical performance shows fluctuating financial metrics, with net sales increasing to 292.56 Cr in March 2025 from 241.29 Cr in March 2024, but declining from 336.43 Cr in March 2023. Profit after tax also decreased to 25.07 Cr in March 2025, down from 35.91 Cr in March 2024 and 45.96 Cr in March 2023.
How has been the historical performance of Balaxi Pharma?
Balaxi Pharma's historical performance shows fluctuating net sales and profits, with net sales increasing to 292.56 Cr in March 2025 but profits declining, resulting in a profit after tax of 25.07 Cr. The company faces challenges in cash generation, as indicated by negative cash flow from operating activities.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
